Welcome to our dedicated page for Privia Health Group SEC filings (Ticker: PRVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Privia Health Group, Inc. files SEC reports that document its physician enablement business, operating results, governance and public-company capital structure. Its 8-K reports commonly furnish quarterly and annual financial releases, including revenue, care margin, platform contribution, adjusted EBITDA, guidance, value-based risk arrangements and provider-network growth.
Proxy and other material-event filings cover board and committee governance, shareholder voting matters, material agreements, risk factors, regulatory disclosures and other updates tied to a Delaware corporation listed on Nasdaq under PRVA.
BERBERIAN LANCE reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group director Lance Berberian reported an equity grant. On May 20, 2026, he received 8,463 restricted stock units under the company’s 2021 Omnibus Incentive Plan. The units will vest on the earlier of the day immediately preceding the 2027 annual stockholders’ meeting or the first anniversary of the grant date.
Following this compensation award, Berberian directly holds 16,131 shares of common stock. The grant was made at no cash cost to him and reflects routine director compensation rather than an open-market purchase or sale.
COCOZZA NANCY G reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group, Inc. director Nancy G. Cocozza reported a stock-based compensation award. On May 20, 2026, she received 8,463 restricted stock units of common stock under the company’s 2021 Omnibus Incentive Plan at no cash cost per share.
The restricted stock units vest on the earlier of the day immediately preceding Privia’s 2027 annual meeting of stockholders or the first anniversary of the grant date. Following this award, Cocozza’s direct holdings reported in the filing total 42,814 shares of common stock.
Kimmet Pamela O reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group director Pamela O. Kimmet received a grant of 8,463 restricted stock units under the company’s 2021 Omnibus Incentive Plan on May 20, 2026. These RSUs vest on the earlier of the day before the 2027 annual shareholder meeting or one year after the grant. After this grant, she holds 34,172 common shares directly. This is a compensation-related award, not an open-market purchase.
McCarthy Thomas A reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group director Thomas A. McCarthy reported an equity award and updated share holdings. On May 20, 2026, he received 8,463 restricted stock units under the company’s 2021 Omnibus Incentive Plan at a grant price of $0.00 per unit.
The restricted stock units vest on the earlier of the day immediately preceding Privia Health’s 2027 annual stockholders’ meeting or the first anniversary of the grant date. Following these entries, McCarthy holds 27,983 common shares directly and 41,487 common shares indirectly through a trust.
Morris Matthew Shawn reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group director Matthew Shawn Morris reported an equity award. On May 20, 2026, he received 8,463 restricted stock units under the company’s 2021 Omnibus Incentive Plan at a grant price of $0.00 per share, increasing his direct holdings to 76,651 common shares.
The restricted stock units will vest on the earlier of the day immediately preceding Privia Health Group’s 2027 annual meeting of stockholders or the first anniversary of the grant date. Separate holding entries show 11,998 common shares held indirectly by a trust and 12,487 common shares held indirectly by Emerald Family, LLC.
Ryu Jaewon reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group director Jaewon Ryu received an equity grant in the form of restricted stock units. On the reported date, he was awarded 8,463 RSUs under the company’s 2021 Omnibus Incentive Plan at no cash cost to him. These RSUs will vest on the earlier of the day immediately preceding Privia’s 2027 annual stockholders’ meeting or the first anniversary of the grant date. Following this award, Ryu directly holds 47,110 shares of Privia common stock, reflecting his ongoing equity-based alignment with the company’s performance.
KING DAVID P reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group, Inc. director David P. King reported an equity compensation grant rather than an open-market trade. On May 20, 2026, he received 8,463 restricted stock units under the company’s 2021 Omnibus Incentive Plan at no cash cost. These RSUs will vest on the earlier of the day immediately preceding the company’s 2027 annual meeting of stockholders or the first anniversary of the grant date. Following this award, he holds 50,775 common shares directly, showing this filing reflects routine director compensation in stock-based form.
Privia Health Group, Inc. director Francis S. Soistman Jr. filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The filing shows no reported transactions and no share positions or derivative holdings at this time for the reporting person.
Privia Health Group, Inc. reported the results of its 2026 Annual Meeting of Stockholders, where all proposals were approved. Stockholders elected three Class I directors — Nancy Cocozza, David King, and Francis Soistman — to terms running until the 2029 annual meeting.
Stockholders also approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers, with 103,956,500 votes cast in favor. In addition, the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 received strong support, with 117,343,159 votes for and minimal opposition.
Privia Health Group, Inc. Chief Executive Officer Parth Mehrotra reported open-market sales of company common stock. He sold 105,439 shares on May 11 at a weighted average price of $22.55 per share and 15,647 shares on May 12 at a weighted average price of $22.64 per share, for total reported sales of 121,086 shares.
According to the footnotes, these sales were effected under a Rule 10b5-1 trading plan, and certain shares were sold on a nondiscretionary "sell to cover" basis to satisfy tax withholding on vested restricted stock units. After these transactions, Mehrotra directly holds 434,357 shares of Privia Health Group common stock. The filing notes that actual sale prices ranged from $22.28 to $23.10 per share.